Objective: There are regional disparities in endovascular thrombectomy, and problems with emergency transport systems and hospital collaboration when transferring need to be addressed. In this study, the clinical outcomes of endovascular thrombectomy for transferred patients were analyzed.
Methods: Acute ischemic stroke patients who underwent endovascular thrombectomy between January 2016 and March 2019 were enrolled. They were retrospectively reviewed and divided into the direct group and transfer group, and we compared treatment results and clinical outcomes between them.
Results: In all, 122 patients met the inclusion criteria, comprising 93 patients in the direct group and 29 patients in the transfer group. The time from onset to door of our hospital was longer in the transfer group than in the direct group (73 minutes vs. 158 minutes, P = 0.80), but the time from arrival to reperfusion was significantly shorter in the transfer group (139 minutes vs. 106 minutes, P = 0.001). As the time from onset to reperfusion did not differ significantly between the two groups (220 minutes vs. 256 minutes, P = 0.60), there was no significant difference in good outcome at discharge (38.7 vs. 41.3%, P = 0.79).
Conclusion: Clinical outcomes of transferred patients for endovascular thrombectomy may be equivalent to those of directly transported patients. Promoting close hospital cooperation may improve clinical outcomes and resolve regional disparities.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370678 | PMC |
| http://dx.doi.org/10.5797/jnet.oa.2019-0098 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Genomic Classifiers on Risk Stratification and Treatment Intensity in Patients With Localized Prostate Cancer : A Systematic Review.
Ann Intern Med
January 2025
Durham VA Health Care System, Durham; and Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, Durham, North Carolina (K.M.G.).
Background: Tissue-based genomic classifiers (GCs) have been developed to improve prostate cancer (PCa) risk assessment and treatment recommendations.
Purpose: To summarize the impact of the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris GCs on risk stratification and patient-clinician decisions on treatment choice among patients with localized PCa considering first-line treatment.
Data Sources: MEDLINE, EMBASE, and Web of Science published from January 2010 to August 2024.
Completeness of Telehealth Interventions Reporting in Randomized Controlled Trials for Caregivers of People With Dementia: Systematic Review.
J Med Internet Res
January 2025
Department of Basic and Community Nursing, School of Nursing, Nanjing Medical University, NanJing, China.
Background: Telehealth interventions can effectively support caregivers of people with dementia by providing care and improving their health outcomes. However, to successfully translate research into clinical practice, the content and details of the interventions must be sufficiently reported in published papers.
Objective: This study aims to evaluate the completeness of a telehealth intervention reporting in randomized controlled trials (RCTs) conducted for caregivers of people with dementia.
A New Smartphone-Based Cognitive Screening Battery for Multiple Sclerosis (icognition): Validation Study.
J Med Internet Res
January 2025
AIMS Lab, Center for Neurosciences, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Background: Cognitive deterioration is common in multiple sclerosis (MS) and requires regular follow-up. Currently, cognitive status is measured in clinical practice using paper-and-pencil tests, which are both time-consuming and costly. Remote monitoring of cognitive status could offer a solution because previous studies on telemedicine tools have proved its feasibility and acceptance among people with MS.
View Article and Find Full Text PDFEfficacy and Safety of Sulforaphane Added to Antipsychotics for the Treatment of Negative Symptoms of Schizophrenia: A Randomized Controlled Trial.
J Clin Psychiatry
January 2025
Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, and Department of Psychiatry, New York University School of Medicine, New York, New York.
There are few established treatments for negative symptoms in schizophrenia, which persist in many patients after positive symptoms are reduced. Oxidative stress, inflammation, and epigenetic modifications involving histone deacetylase (HDAC) have been implicated in the pathophysiology of schizophrenia. Sulforaphane has antioxidant properties and is an HDAC inhibitor.
View Article and Find Full Text PDFEfficacy and Safety of BI 1358894 in Patients With Borderline Personality Disorder: Results of a Phase 2 Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Trial.
J Clin Psychiatry
January 2025
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York.
To provide proof-of-concept (PoC), dose-range finding, and safety data for BI 1358894, a TRPC4/5 ion channel inhibitor, in patients with borderline personality disorder (BPD). This was a phase 2, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to oral placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) once daily in a 2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!